Cargando…
SVR Rates of HCV-infected population under PEG-IFN-α/R treatment in Northwest China
BACKGROUND: Chronic HCV Patients taking PEG-IFN-α/R from different ethnic groups have different probabilities of reaching a sustained viral response (SVR). There are many influence factors, such as HCV genotype, IL-28B single-nucleotide polymorphisms (SNP), Fibrosis 4 index (FIB-4), and aspartate am...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5364675/ https://www.ncbi.nlm.nih.gov/pubmed/28335783 http://dx.doi.org/10.1186/s12985-017-0708-6 |
_version_ | 1782517371716501504 |
---|---|
author | Li, Yanhua Wang, Jiuping Wang, Juan Xiao, Yunfeng Xu, Bin Li, Hongwei Yang, Liu Hao, Xiaoke Ma, Yueyun |
author_facet | Li, Yanhua Wang, Jiuping Wang, Juan Xiao, Yunfeng Xu, Bin Li, Hongwei Yang, Liu Hao, Xiaoke Ma, Yueyun |
author_sort | Li, Yanhua |
collection | PubMed |
description | BACKGROUND: Chronic HCV Patients taking PEG-IFN-α/R from different ethnic groups have different probabilities of reaching a sustained viral response (SVR). There are many influence factors, such as HCV genotype, IL-28B single-nucleotide polymorphisms (SNP), Fibrosis 4 index (FIB-4), and aspartate aminotransferase-to-platelet ratio index (APRI) score. But the baseline factors in relation to treatment outcome was still not much clear. METHODS: We evaluated data from 231 chronic HCV patients with or without liver fibrosis and their antiviral efficacy after treatment with pegylated interferon plus ribavirin (PEG-IFN-α/R) for 24–48 weeks. IL-28B SNP and HCV genotypes were analyzed with genome sequencing using pyrosequencing. RESULTS: Sustained viral response (SVR) rates of patients with HCV 1b and 2a genotypes were 52.25% (58/111) and 75.28% (67/89) (P < 0.01). SVR rates of patients with IL-28B rs8099917 TT, rs12979860 CC and rs12980275 AA were 92.41% (25/27), 92.86% (26/28) and 88.89% (24/27) separately. We found that SVR rates in HCV 1b and 2a patients were only 31.0 and 39.4% if their FIB-4 > 3.25. In addition, when their APRI > 2, only 30.3% of HCV 1b patients and 50.2% of HCV 2a patients could obtain SVR. CONCLUSIONS: There were high proportion of HCV genotype 1b and 2a in Northwest China. In both HCV 1b and 2a genotypes, patients with protective-genotype of IL-28B were more likely to obtain SVR. However, those with significant fibrosis or cirrhosis were less likely, no matter their genotype. Combined factors of HCV genotype, IL-28B genotype, FIB-4 and ARPI may indicate high prediction and clinical value regarding treatment with PEG-IFN-α/R and prognostic evaluation of chronic hepatitis C patients. |
format | Online Article Text |
id | pubmed-5364675 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-53646752017-03-24 SVR Rates of HCV-infected population under PEG-IFN-α/R treatment in Northwest China Li, Yanhua Wang, Jiuping Wang, Juan Xiao, Yunfeng Xu, Bin Li, Hongwei Yang, Liu Hao, Xiaoke Ma, Yueyun Virol J Research BACKGROUND: Chronic HCV Patients taking PEG-IFN-α/R from different ethnic groups have different probabilities of reaching a sustained viral response (SVR). There are many influence factors, such as HCV genotype, IL-28B single-nucleotide polymorphisms (SNP), Fibrosis 4 index (FIB-4), and aspartate aminotransferase-to-platelet ratio index (APRI) score. But the baseline factors in relation to treatment outcome was still not much clear. METHODS: We evaluated data from 231 chronic HCV patients with or without liver fibrosis and their antiviral efficacy after treatment with pegylated interferon plus ribavirin (PEG-IFN-α/R) for 24–48 weeks. IL-28B SNP and HCV genotypes were analyzed with genome sequencing using pyrosequencing. RESULTS: Sustained viral response (SVR) rates of patients with HCV 1b and 2a genotypes were 52.25% (58/111) and 75.28% (67/89) (P < 0.01). SVR rates of patients with IL-28B rs8099917 TT, rs12979860 CC and rs12980275 AA were 92.41% (25/27), 92.86% (26/28) and 88.89% (24/27) separately. We found that SVR rates in HCV 1b and 2a patients were only 31.0 and 39.4% if their FIB-4 > 3.25. In addition, when their APRI > 2, only 30.3% of HCV 1b patients and 50.2% of HCV 2a patients could obtain SVR. CONCLUSIONS: There were high proportion of HCV genotype 1b and 2a in Northwest China. In both HCV 1b and 2a genotypes, patients with protective-genotype of IL-28B were more likely to obtain SVR. However, those with significant fibrosis or cirrhosis were less likely, no matter their genotype. Combined factors of HCV genotype, IL-28B genotype, FIB-4 and ARPI may indicate high prediction and clinical value regarding treatment with PEG-IFN-α/R and prognostic evaluation of chronic hepatitis C patients. BioMed Central 2017-03-23 /pmc/articles/PMC5364675/ /pubmed/28335783 http://dx.doi.org/10.1186/s12985-017-0708-6 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Li, Yanhua Wang, Jiuping Wang, Juan Xiao, Yunfeng Xu, Bin Li, Hongwei Yang, Liu Hao, Xiaoke Ma, Yueyun SVR Rates of HCV-infected population under PEG-IFN-α/R treatment in Northwest China |
title | SVR Rates of HCV-infected population under PEG-IFN-α/R treatment in Northwest China |
title_full | SVR Rates of HCV-infected population under PEG-IFN-α/R treatment in Northwest China |
title_fullStr | SVR Rates of HCV-infected population under PEG-IFN-α/R treatment in Northwest China |
title_full_unstemmed | SVR Rates of HCV-infected population under PEG-IFN-α/R treatment in Northwest China |
title_short | SVR Rates of HCV-infected population under PEG-IFN-α/R treatment in Northwest China |
title_sort | svr rates of hcv-infected population under peg-ifn-α/r treatment in northwest china |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5364675/ https://www.ncbi.nlm.nih.gov/pubmed/28335783 http://dx.doi.org/10.1186/s12985-017-0708-6 |
work_keys_str_mv | AT liyanhua svrratesofhcvinfectedpopulationunderpegifnartreatmentinnorthwestchina AT wangjiuping svrratesofhcvinfectedpopulationunderpegifnartreatmentinnorthwestchina AT wangjuan svrratesofhcvinfectedpopulationunderpegifnartreatmentinnorthwestchina AT xiaoyunfeng svrratesofhcvinfectedpopulationunderpegifnartreatmentinnorthwestchina AT xubin svrratesofhcvinfectedpopulationunderpegifnartreatmentinnorthwestchina AT lihongwei svrratesofhcvinfectedpopulationunderpegifnartreatmentinnorthwestchina AT yangliu svrratesofhcvinfectedpopulationunderpegifnartreatmentinnorthwestchina AT haoxiaoke svrratesofhcvinfectedpopulationunderpegifnartreatmentinnorthwestchina AT mayueyun svrratesofhcvinfectedpopulationunderpegifnartreatmentinnorthwestchina |